Why the study?
Does pravastatin 10 mg per day prevent recurrent events in Japanese patients with previous non-cardioembolic ischaemic stroke?
Does pravastatin 10 mg per day prevent recurrent events in Japanese patients with previous non-cardioembolic ischaemic stroke?
Answers are grounded in this paper and cite their sources.
This editorial discusses the J-STARS trial, which evaluated the efficacy of low-dose pravastatin for secondary prevention in Japanese patients with prior non-cardioembolic ischemic stroke.
In this issue of EBioMedicine, Naohisa Hosomi and colleagues report the eagerly awaited results of the Japan Statin Treatment Against Recurrent Stroke (J-STARS) trial (Hosomi et al., in press). A total of 1578 Japanese men and women aged 45 to 80years with previous non-cardioembolic ischaemic stroke and total cholesterol concentration between 4.65 and 6.21mmol/l were randomly assigned to open-label pravastatin 10mg per day or to control (no statin, but non-statin drugs were allowed) and followed for a mean of 4.9years (Hosomi et al., in press).
No takes yet. Share an insight, caveat, or question.
Graeme J. Hankey (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: